

Mastering migraine

Comprehensive treatment solutions for episodic and chronic migraine (including injection hands-on training)

10.10.2026, 09:00h
Welle 7, Bern

AbbVie Medical Institute

NEUROLITE
Advanced Medical Solutions

Promotional meeting organised and funded by AbbVie.

abbvie

Dear Healthcare Professionals.

We are delighted to invite you to the comprehensive AMI (AbbVie Medical Institute) workshop focused on the treatment of patients with episodic and chronic migraine. This workshop will provide in-depth insights into the mode of action of botulinum toxin and atogepant, along with hands-on injector training and discussions on the PREEMPT trial and phase 3 clinical studies.

Workshop Agenda

- **Understanding Migraine Pathophysiology:**
Gain a comprehensive understanding of both episodic and chronic migraine. Explore the mechanisms underlying migraine attacks.
- **Botulinum Toxin in Migraine Treatment:**
Learn the mode of action of botulinum toxin in migraine treatment. Review the clinical evidence and efficacy of botulinum toxin for migraine. Understand patient selection criteria and dosing strategies. Participate in a hands-on injector training session.
- **The PREEMPT Trial*:**
Review the pivotal PREEMPT clinical trial on botulinum toxin for chronic migraine. Discuss key findings and their implications for clinical practice.
- **Atogepant in Migraine Treatment:**
Understand the mode of action and pharmacology of atogepant. Review the results from phase 3 clinical studies on atogepant. Discuss the efficacy, safety, and patient selection criteria for atogepant.
- **Interactive Case Studies:**
Engage in discussion of real-world migraine cases. Improve decision-making skills in migraine management.
- **Q&A Session:**
Open forum for questions and discussions

Objectives



Gain a comprehensive understanding of both episodic and chronic migraine.



Learn the mode of action of botulinum toxin in migraine treatment.



Review the pivotal PREEMPT clinical trial on botulinum toxin for chronic migraine.



Understand the mode of action and pharmacology of atogepant.



Engage in discussion of real-world migraine cases.

PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy
* Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011 Oct;51(9):1358-73


The references can be requested by professionals at medinfo.ch@abbvie.com
Adverse events should be reported. Reporting forms and information can be found at www.swissmedic.ch. Adverse events should also be reported to Pharmacovigilance.ch@abbvie.com.

AbbVie AG : Summary of Product Characteristics BOTOX®: www.swissmedicinfo-pro.ch
AbbVie AG : Summary of Product Characteristics AQUIPTA®: www.swissmedicinfo-pro.ch

Time	Workshop Details
09:00 - 10:00	Understanding Migraine Pathophysiology Botulinum Toxin in Chronic Migraine Treatment The PREEMPT Trial
10:00 - 10:15	Break
10:15 - 11:30	Atogepant in Migraine Treatment Interactive Case Studies
11:30 - 13:00	Hands-On Training Q&A followed by an apero

Mastering migraine

Language: German/English
Date: 10.10.2026
Time: 09:00 – 13:00
Venue: Welle 7, Bern
Speakers: *Prof. Christoph Schankin*
Leitender Arzt,
Leiter Sprechstunde Kopfschmerzen
INSELSpital, Universitätsklinik für Neurologie
Dr. Julia Waskönig
Oberärztin,
Leitung Botulinumtoxin-Sprechstunde
INSELSpital, Universitätsklinik für Neurologie
Credits: The workshop will be credited with 4 CME points according SNG
Sponsors: This workshop will be co-sponsored by Neurolite



- ◀ Please register your interest for this Workshop
- ◀ Before attending the AMI chronic migraine workshop we recommend completing the chronic migraine e-modules



We look forward to your participation and lively discussions at this AMI Workshop

Sincerely,

Katrin-Caroline Voigt

AbbVie Medical Institute AMI